These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 24578241)

  • 1. Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling.
    Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Lyerly HK; Zalutsky MR
    J Nucl Med; 2014 Apr; 55(4):650-6. PubMed ID: 24578241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK.
    Vaidyanathan G; Jestin E; Olafsen T; Wu AM; Zalutsky MR
    Nucl Med Biol; 2009 Aug; 36(6):671-80. PubMed ID: 19647173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: influence of isomeric substitution on radiolabeling and target cell residualization.
    Choi J; Vaidyanathan G; Koumarianou E; McDougald D; Pruszynski M; Osada T; Lahoutte T; Lyerly HK; Zalutsky MR
    Nucl Med Biol; 2014; 41(10):802-12. PubMed ID: 25156548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET.
    Vaidyanathan G; McDougald D; Choi J; Koumarianou E; Weitzel D; Osada T; Lyerly HK; Zalutsky MR
    J Nucl Med; 2016 Jun; 57(6):967-73. PubMed ID: 26912425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.
    Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Zalutsky MR
    Nucl Med Biol; 2013 Jan; 40(1):52-9. PubMed ID: 23159171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent.
    Feng Y; Zhou Z; McDougald D; Meshaw RL; Vaidyanathan G; Zalutsky MR
    Nucl Med Biol; 2021 Jan; 92():171-183. PubMed ID: 32448731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation.
    Zhou Z; Vaidyanathan G; McDougald D; Kang CM; Balyasnikova I; Devoogdt N; Ta AN; McNaughton BR; Zalutsky MR
    Mol Imaging Biol; 2017 Dec; 19(6):867-877. PubMed ID: 28409338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Observations on the Effects of Residualization and Dehalogenation on the Utility of
    Chitneni SK; Koumarianou E; Vaidyanathan G; Zalutsky MR
    Molecules; 2019 Oct; 24(21):. PubMed ID: 31671554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation.
    Zhou Z; Chitneni SK; Devoogdt N; Zalutsky MR; Vaidyanathan G
    Bioorg Med Chem; 2018 May; 26(8):1939-1949. PubMed ID: 29534937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation.
    Choi J; Vaidyanathan G; Koumarianou E; Kang CM; Zalutsky MR
    Nucl Med Biol; 2018 Jan; 56():10-20. PubMed ID: 29031230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Site-Specific and Residualizing Linker for
    Zhou Z; Meshaw R; Zalutsky MR; Vaidyanathan G
    J Nucl Med; 2021 Nov; 62(11):1624-1630. PubMed ID: 33637584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[
    Zhou Z; McDougald D; Devoogdt N; Zalutsky MR; Vaidyanathan G
    Mol Pharm; 2019 Jan; 16(1):214-226. PubMed ID: 30427188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodination.
    Pruszynski M; Koumarianou E; Vaidyanathan G; Chitneni S; Zalutsky MR
    Nucl Med Biol; 2015 Jan; 42(1):19-27. PubMed ID: 25240914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Labeling single domain antibody fragments with
    Zhou Z; McDougald D; Meshaw R; Balyasnikova I; Zalutsky MR; Vaidyanathan G
    Nucl Med Biol; 2021; 100-101():24-35. PubMed ID: 34146837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. d-Amino Acid Peptide Residualizing Agents for Protein Radioiodination: Effect of Aspartate for Glutamate Substitution.
    Pruszynski M; Kang CM; Koumarianou E; Vaidyanathan G; Zalutsky MR
    Molecules; 2018 May; 23(5):. PubMed ID: 29783774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of an Anti-HER2 Nanobody Labeled with
    Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T
    Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of [
    Ducharme M; Hall L; Eckenroad W; Cingoranelli SJ; Houson HA; Jaskowski L; Hunter C; Larimer BM; Lapi SE
    Mol Pharm; 2023 Sep; 20(9):4629-4639. PubMed ID: 37552575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A polar substituent-containing acylation agent for the radioiodination of internalizing monoclonal antibodies: N-succinimidyl 4-guanidinomethyl-3-[131I]iodobenzoate ([131I]SGMIB).
    Vaidyanathan G; Affleck DJ; Li J; Welsh P; Zalutsky MR
    Bioconjug Chem; 2001; 12(3):428-38. PubMed ID: 11353542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Labeling a TCO-functionalized single domain antibody fragment with
    Zhou Z; Zalutsky MR; Vaidyanathan G
    Bioorg Med Chem; 2020 Sep; 28(17):115634. PubMed ID: 32773089
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.